Journal article · 2024 · Open access

Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study

Jean‐Paul Pirnay, Sarah Djebara, Griet Steurs, Johann Griselain, Christel Cochez, Steven De Soir, Téa Glonti, An Spiessens, Emily Vanden Berghe, Sabrina I. Green, Jeroen Wagemans, Cédric Lood and 91 more

Nature Microbiology, 9(6), 1434–1453 · Published 4 June 2024 · DOI 10.1038/s41564-024-01705-x

Free PDFView at the publisherCite this paper

In brief

“Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study” is a 2024 journal article by Jean‐Paul Pirnay and 102 co-authors, published in Nature Microbiology. OpenAlex counts 551 citations as of 15 November 2026, which puts it in the top 4% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Nature Microbiology.

Citations
551
Most cited in
2026 (252)
Field-weighted impact
79.45
References
103
Authors
103

Abstract

In contrast to the many reports of successful real-world cases of personalized bacteriophage therapy (BT), randomized controlled trials of non-personalized bacteriophage products have not produced the expected results. Here we present the outcomes of a retrospective observational analysis of the first 100 consecutive cases of personalized BT of difficult-to-treat infections facilitated by a Belgian consortium in 35 hospitals, 29 cities and 12 countries during the period from 1 January 2008 to 30 April 2022. We assessed how often personalized BT produced a positive clinical outcome (general efficacy) and performed a regression analysis to identify functional relationships. The most common indications were lower respiratory tract, skin and soft tissue, and bone infections, and involved combinations of 26 bacteriophages and 6 defined bacteriophage cocktails, individually selected and sometimes pre-adapted to target the causative bacterial pathogens. Clinical improvement and eradication of the targeted bacteria were reported for 77.2% and 61.3% of infections, respectively. In our dataset of 100 cases, eradication was 70% less probable when no concomitant antibiotics were used (odds ratio = 0.3; 95% confidence interval = 0.127-0.749). In vivo selection of bacteriophage resistance and in vitro bacteriophage-antibiotic synergy were documented in 43.8% (7/16 patients) and 90% (9/10) of evaluated patients, respectively. We observed a combination of antibiotic re-sensitization and reduced virulence in bacteriophage-resistant bacterial isolates that emerged during BT. Bacteriophage immune neutralization was observed in 38.5% (5/13) of screened patients. Fifteen adverse events were reported, including seven non-serious adverse drug reactions suspected to be linked to BT. While our analysis is limited by the uncontrolled nature of these data, it indicates that BT can be effective in combination with antibiotics and can inform the design of future controlled clinical trials. BT100 study, ClinicalTrials.gov registration: NCT05498363 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Pirnay, J., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., Glonti, T., Spiessens, A., Berghe, E. V., Green, S. I., Wagemans, J., Lood, C., Schrevens, E. L., Чанішвілі, Н., Kutateladze, M., de Jode, M., Ceyssens, P., Draye, J., Verbeken, G., . . . Merabishvili, M. (2024). Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nature Microbiology, 9(6), 1434–1453. https://doi.org/10.1038/s41564-024-01705-x

MLA 9

Pirnay, Jean‐Paul, et al. “Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.” Nature Microbiology, vol. 9, no. 6, 2024, pp. 1434–1453. https://doi.org/10.1038/s41564-024-01705-x.

Chicago

Pirnay, Jean‐Paul, Sarah Djebara, Griet Steurs, Johann Griselain, Christel Cochez, Steven De Soir, Téa Glonti, et al. 2024. “Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.” Nature Microbiology 9 (6): 1434–1453. https://doi.org/10.1038/s41564-024-01705-x.

Harvard

Pirnay, J. et al. (2024) ‘Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study’, Nature Microbiology, 9(6), pp. 1434–1453. doi:10.1038/s41564-024-01705-x.

IEEE

J. Pirnay et al., “Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study,” Nature Microbiology, vol. 9, no. 6, pp. 1434–1453, 2024, doi: 10.1038/s41564-024-01705-x.

BibTeX

@article{pirnay2024personalized,
  title     = {{Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study}},
  author    = {Pirnay, Jean‐Paul and Djebara, Sarah and Steurs, Griet and Griselain, Johann and Cochez, Christel and De Soir, Steven and Glonti, Téa and Spiessens, An and Berghe, Emily Vanden and Green, Sabrina I. and Wagemans, Jeroen and Lood, Cédric and Schrevens, Eddie L. and Чанішвілі, Ніна and Kutateladze, Mzia and de Jode, Mathieu and Ceyssens, Pieter‐Jan and Draye, Jean‐Pierre and Verbeken, Gilbert and De Vos, Daniël and Rose, Thomas and Onsea, Jolien and Van Nieuwenhuyse, Brieuc and Providers, Bacteriophage Therapy and Pang, Kim Win and Metsemakers, Willem‐Jan and Van der Linden, Dimitri and Chatzis, Olga and Eskenazi, Anaïs and Lopez, Angel and others},
  journal   = {Nature Microbiology},
  year      = {2024},
  volume    = {9},
  number    = {6},
  pages     = {1434--1453},
  doi       = {10.1038/s41564-024-01705-x},
  url       = {https://doi.org/10.1038/s41564-024-01705-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202344
20247070
2025225225
2026252252

Its field-weighted citation impact is 79.45: it has been cited 79.45 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions

  • phage therapy
  • difficult-to-treat infections
  • phage cocktail
  • combination antibiotic therapy
  • phage resistance
  • phage-antibiotic synergy
  • adverse drug reactions
  • lower respiratory tract infection

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Pirnay, J., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., Glonti, T., Spiessens, A., Berghe, E. V., Green, S. I., Wagemans, J., Lood, C., Schrevens, E. L., Чанішвілі, Н., Kutateladze, M., de Jode, M., Ceyssens, P., Draye, J., Verbeken, G., . . . Merabishvili, M. (2024). Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nature Microbiology, 9(6), 1434–1453. https://doi.org/10.1038/s41564-024-01705-x

How many times has this paper been cited?

551 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Nature Microbiology.

Who wrote this paper?

Jean‐Paul Pirnay, Sarah Djebara, Griet Steurs, Johann Griselain, Christel Cochez, Steven De Soir, Téa Glonti, An Spiessens, Emily Vanden Berghe, Sabrina I. Green, Jeroen Wagemans, Cédric Lood and 91 more.

What is the DOI of this paper?

10.1038/s41564-024-01705-x. The permanent link is https://doi.org/10.1038/s41564-024-01705-x.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.